Back to How We Help Clients

Research & Development

Helping clients build the R&D capabilities needed to drive innovation, improve productivity and performance, and develop successful portfolio and asset strategies.

What we do

Our R&D clients include major pharmaceutical companies, medical device manufacturers, biotechs, and clinical research organizations. Our work, which spans all major therapeutic areas, focuses on:

Driving innovation

We can help transform a company's corporate culture and R&D infrastructure to meet changing industry needs, or support efforts to attract, motivate, and mobilize the best talent. We use our insights to help companies develop innovative products that offer substantial benefits over existing therapies, allowing them to overcome hurdles to regulatory approval and payor reimbursement.

Improving productivity and performance

We have multiple strategies for enhancing client's productivity and performance. For instance, we can help them access new technologies and innovation through various R&D financing and partnership models that minimize cost and risk. We also facilitate approval and reduce development timelines and costs by helping design clinical strategies that maximize the chance for a successful approval with the best possible label. Our efforts often involve assisting companies with organizational issues (e.g., helping them determine the most efficient structure post-merger, etc.). Since we understand the changing vendor landscape and we offer global reach and expertise, we can also assist companies in identifying the right outsourcing/off-shoring opportunities and in capturing greater value from emerging markets.

Developing successful portfolio and asset strategies

For resource allocation, we help clients allocate their clinical research budgets and focus on the most promising products. With existing drugs and devices, we show clients which therapy areas, diseases, or products should receive priority. Most importantly, we apply novel approaches to maximize the value creation potential of each individual pipeline asset. For instance, we can help clients identify compounds that will provide more value in established markets or generate demand in rapidly growing emerging markets. We also help clients identify and execute business development opportunities, including in- and out-licensing deals, mergers and acquisitions, joint ventures, and innovative multi-party transactions that improve productivity.

Optimizing medical and regulatory affairs organization and strategy

We help Medical and Regulatory Affairs divisions to implement best practice organizational set-ups and build the capabilities required to meet the expectations of external shareholders. We also support clients in their pursuit of product safety and clinical quality excellence.

Forging connections

We regularly convene industry conferences on R&D issues. A few examples:

  • The Medical Affairs Leadership Academy, a 'field and forum' programme that aims to heighten the business and leadership capabilities of Medical Affairs divisions in our clients
  • The R&D Leadership Development Forum, which helps rising executives at pharmaceutical and biotech companies network and share their perspectives
  • Semi-annual CMC Forums, which include annual benchmarking and knowledge sharing on priority topics, attended by leading pharmaceutical and biotech companies
  • We also frequently give R&D presentations at investor meetings and conferences including the Lindau Nobel Laureate Meeting and Citi's Global Healthcare Conference and have published in Nature Reviews Drug Discovery on topics including R&D productivity, trends in clinical trial success rates, and sourcing pharmaceutical innovation

Featured experts

Michael Steinmann

Managing Partner Switzerland, Zurich

Jeffrey Algazy

Senior Partner, New Jersey

Lucy Pérez

Senior Partner, Boston

Related Insights


Clinical supply chains: How to boost excellence and innovation

– Clinical trials have increased in number and have become more complex, decentralized, and patient-centric. While this puts pressure... on clinical drug supply, it also brings new opportunities.

The dawn of China biopharma innovation

– Chinese biopharma is making a mark on the global stage as the rapidly evolving regulatory landscape and maturing innovation ecosystem... spur significant value creation.

Getting strategic about new-product submissions in the pharma industry

– By rethinking the approach to regulatory submissions, pharma companies can reduce timelines and increase their chances of successful... product approvals.

No place like home? Stepping up the decentralization of clinical trials

– The COVID-19 pandemic has catalyzed the adoption of decentralized clinical trials while highlighting the critical benefits of... virtual trials and improving the patient and physician experience.

A new portfolio model for biotech

– An emerging model for biotech companies could disrupt the R&D landscape and open up new ways to invest, motivate teams, and... shape the innovation pipeline.

Amgen’s Brian Bradbury on advancing healthcare through data analytics

– Brian Bradbury of Amgen’s Center for Observational Research discusses the power of data and analytics to advance the understanding... of disease, therapeutic interventions, and clinical outcomes.

Recalculating the future of drug development with quantum computing

– Two experts discuss how quantum computing can help solve intractable problems in drug discovery and development.

COVID-19 implications for life sciences R&D: Recovery and the next normal

– COVID-19 has severely disrupted pharma and medtech R&D. Leaders should prepare along three horizons—safeguarding patients... and employees, adapting operations for a recovery, and building for the next normal.

Unlocking the power of translational medicine

– By strengthening current translational medicine (TM) practices and preparing for advances, organizations could enhance the power... of TM and increase its influence on R&D productivity overall.